Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - CANTEL MEDICAL LLC | a12-6747_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 6, 2012
CANTEL MEDICAL CORP.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-31337 |
|
22-1760285 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Identification |
|
of incorporation) |
|
File Number) |
|
Number) |
|
150 Clove Road, Little Falls, New Jersey |
|
07424 |
|
Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (973) 890-7220
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On March 8, 2012, the Registrant issued a press release announcing its results of operations for the quarter ended January 31, 2012 (Registrant’s second quarter of fiscal year 2012). A copy of the press release is included with this Report as Exhibit 99.1.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers .
On March 6, 2012, Mr. Seth R. Segel, Executive Vice President, submitted his resignation to the Company. Mr. Segel will remain employed by the Company until on or about March 16, 2012. Mr. Segel indicated that he will be leaving the Company to serve as President and Chief Executive Officer of a privately-owned specialty distributor of urology products based in New York.
The Company’s acquisition program, led by Mr. Segel, will continue unabated through internal and external resources. The Company has commenced the recruitment of a replacement for Mr. Segel’s position.
Item 9.01 Financial Statements, Pro-Forma Financial Information and Exhibits
(d) Exhibit 99.1 Press release of Registrant dated March 8¸ 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
CANTEL MEDICAL CORP. | |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Andrew A. Krakauer |
|
|
|
Andrew A. Krakauer |
|
|
|
President and CEO |
Dated: March 8, 2012